Bluebird Bio Inc. (NASDAQ:BLUE)’s share price traded up 4.2% on Tuesday . The company traded as high as $74.74 and last traded at $73.96, with a volume of 837,137 shares. The stock had previously closed at $70.95.

A number of equities research analysts recently issued reports on BLUE shares. Goldman Sachs Group Inc. raised Bluebird Bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price target on the stock in a research report on Thursday, September 15th. Maxim Group reissued a “buy” rating and set a $85.00 price target on shares of Bluebird Bio in a research report on Monday, September 12th. BTIG Research reissued a “buy” rating and set a $72.00 price target on shares of Bluebird Bio in a research report on Sunday, September 11th. Cowen and Company reissued an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Finally, Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $87.39.

The company’s market capitalization is $2.75 billion. The stock has a 50-day moving average of $55.99 and a 200 day moving average of $47.78.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/bluebird-bio-inc-blue-trading-4-2-higher.html

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter last year, the firm posted ($1.57) earnings per share. The firm’s revenue was down 68.6% on a year-over-year basis. On average, equities research analysts anticipate that Bluebird Bio Inc. will post ($6.16) earnings per share for the current year.

In other Bluebird Bio news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the completion of the sale, the insider now directly owns 4,656 shares in the company, valued at $209,706.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the sale, the insider now owns 10,600 shares of the company’s stock, valued at $477,848. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Bluebird Bio during the first quarter valued at about $51,095,000. BlackRock Inc. raised its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the last quarter. California State Teachers Retirement System raised its stake in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock valued at $3,363,000 after buying an additional 1,682 shares during the last quarter. Iguana Healthcare Management LLC acquired a new stake in Bluebird Bio during the first quarter valued at about $1,030,000. Finally, Swiss National Bank raised its stake in Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.